Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 4(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00777231Phase 1Completed

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

Role: collaborator

NCT01093131Phase 4Withdrawn

Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy

Role: lead

NCT01050348Phase 4Completed

To Investigate the Role of Upstream High Dose Statin in STEMI

Role: lead

All 3 trials loaded